Pfizer Is to Merge Off-Patent Drug Unit With Mylan

Pfizer agreed on Monday to combine its off-patent drugs division, which controls treatments like the statin Lipitor, with the pharmaceutical company Mylan, creating a potential powerhouse in the business of medicines without patent protections. The transaction comes as falling prices increase pressure on generic drugmakers, a development that has been mostly overlooked in the United…